Accumetrics, Daiichi Sankyo, and Eli Lilly and Company announced in July that the companies have...
Accumetrics, Inc., developer and marketer of the VerifyNow® System, has announced that 2009 has seen a doubling in the number of international and US distribution agreements, as well as positive medical community support and significant capital financing that will take the company into 2011.
In 2009, the company continued its commitment to creating a powerful, worldwide distribution network to gain adoption of its products at end-user levels. Spanning Europe, Latin America and Asia, Accumetrics currently has partnerships with 20 leading international distributors who provide the company with local representation in over 30 countries. Latest additions to the international distribution network include Keller Medical in Germany, ZAO Schag in Russia and VSA Alta Complejidad S.A. in Argentina.
Accumetrics has continued to strengthen its US presence by partnering with ten cardiovascular specialty distributors to enhance support to the company’s growing base of clinicians in the domestic hospital market. Accumetrics has also partnered with National Distribution & Contracting, Inc. (NDC), the largest organisation of independent medical supply distributors in North America, to expand its distribution network in the physician office lab marketplace.
Increasing evidence of the clinical value of platelet reactivity testing was demonstrated in several presentations of new clinical studies including the POPular study, presented at the American Heart Association Scientific Sessions in November, and a meta-analysis presented at a symposium during the 2009 Transcatheter Cardiovascular Therapeutics Conference. These data also build upon the anticipation of the results of the GRAVITAS trial, which has now completed 80% enrolment.
Growing clinical acceptance
“2009 has proven to be an outstanding year of growth for Accumetrics,” said Timothy I. Still, CEO and president of Accumetrics. “We look at 2010 as a breakthrough year for the company and are pleased to be in a position to capitalise on the growing clinical acceptance of platelet reactivity testing.”
Accumetrics concluded 2009 with $17.1 million in new capital financing, which will fully support the company into 2011. Proceeds will fund a number of milestones set for 2010, including expanded claims for existing products, new product development and continued expansion of commercialisation efforts.
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics’ VerifyNow System is the first rapid and easy to use platform for measuring an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors such as prasugrel and clopidogrel, and GP IIb/IIIa inhibitors such as ReoPro® and Integrilin®, the VerifyNow System provides a valuable tool to help physicians make more informed treatment decisions.
Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who Have Undergone PCI
Accumetrics, a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use...
Accumetrics, Inc., developer and marketer of the VerifyNow® System, has received a certificate of registration...